Clinical Trial: Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx
Study Status: Not yet recruiting
Recruit Status: Unknown status
Study Type: Interventional
Official Title: Phase II Study of Immunotherapy With Autogenous Papilloma Vaccine in Patients With Recurrent Juvenile Papilloma of the Larynx
Brief Summary:
RATIONALE: Vaccines made from papilloma virus cells may make the body build an immune response to and kill papilloma cells.
PURPOSE: Phase II trial to study the effectiveness of papilloma virus vaccine in treating young patients with recurrent papilloma of the larynx.
Detailed Summary:
OBJECTIVES: I. Determine the immune response in patients with juvenile papilloma of the larynx treated with autogenous vaccine derived from each patient's own tumor.
OUTLINE: Patients receive autogenous papilloma vaccine intradermally and subcutaneously weekly for 20 weeks.
PROJECTED ACCRUAL: Not specified
Sponsor: University of Medicine and Dentistry of New Jersey
Current Primary Outcome:
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: National Cancer Institute (NCI)
Dates:
Date Received: November 1, 1999
Date Started: December 1971
Date Completion:
Last Updated: July 23, 2011
Last Verified: January 2002